Uni

Bandai Co., Ltd. Partners With Xsolla to Launch the "Tamaverse Ticket Shop" Online

Retrieved on: 
Tuesday, April 16, 2024
Technology, Electronic Games, Entertainment, Electronic Commerce, Metaverse, Mobile Entertainment, Software, Internet, Retail, Online Retail, Multimedia, Partnership, Uni, PC

Xsolla, a global video game commerce company, has successfully helped power the Tokyo-based game "Tamagotchi Uni," a Bandai Co., Ltd. service offered through the Xsolla Web Shop technology.

Key Points: 
  • Xsolla, a global video game commerce company, has successfully helped power the Tokyo-based game "Tamagotchi Uni," a Bandai Co., Ltd. service offered through the Xsolla Web Shop technology.
  • Specializing in advanced game payment solutions for developers across various platforms, including mobile, PC, cloud, and the web, Xsolla is committed to enhancing player engagement and fulfilling the needs of gamers around the globe.
  • Additionally, leveraging this solution to support payment solutions in various countries worldwide contributes to securing global reach, scale, and revenue for "Tamagotchi Uni."
  • David Stelzer, President of Xsolla, expressed his excitement about the collaboration: "Partnering with Bandai Co., Ltd. to integrate our cutting-edge payment solutions into 'Tamagotchi Uni' represents a significant milestone.

TME Chart 2023 Year-End Charts Officially Unveiled, Featuring Notable Artists including Joker Xue, Zhou Shen and Tia Ray

Retrieved on: 
Friday, January 26, 2024
Dark, Streamflow, Tencent Music, Music, Tristesse, Meet Yourself, Uni, Multimedia, Chart, Female, Male, Attention, Environment, Suzume, Christmas Star, Human, TME, Growth

SHENZHEN, China, Jan. 25, 2024 /PRNewswire/ -- TME Chart, one of the brand of Tencent Music Entertainment Group, officially released the TME Chart 2023 Year-End Charts on January 23rd, featuring three main categories: General Chart, Uni Chart, and Wave Chart.

Key Points: 
  • SHENZHEN, China, Jan. 25, 2024 /PRNewswire/ -- TME Chart, one of the brand of Tencent Music Entertainment Group, officially released the TME Chart 2023 Year-End Charts on January 23rd, featuring three main categories: General Chart, Uni Chart, and Wave Chart.
  • A major overhaul characterized the 2023 Year-End Charts, sponsored by JD Supermarket, to present the TME Chart Year-End Chart special series.
  • Furthermore, TME Chart 2023 Year-End Charts combine the comprehensive results from both the Uni Chart and Wave Chart to select and present the Top 10 Songs and Top 10 Artists of the year.
  • The Top 10 Artists showcase prominent figures such as Zhou Shen, Zhang Bichen, Dao Lang, Joker Xue, and Tia Ray.

$X Project Unveils X-Shot Sniper BOT: Redefining Crypto Trading

Retrieved on: 
Monday, October 30, 2023
Maestro, Rest, Growth, Social media, Investment, BOT, Ecosystem, Uni, Heart, Telescopic sight, Cryptocurrency

This state-of-the-art trading tool is set to revolutionize the way traders engage with the market.

Key Points: 
  • This state-of-the-art trading tool is set to revolutionize the way traders engage with the market.
  • Designed for traders seeking a competitive edge, X-Shot is positioned to outperform industry stalwarts like Maestro and Unibot Sniper Bots.
  • Boasting lightning-fast execution and an array of premium features, X-Shot is poised to take crypto trading to unparalleled heights.
  • For more information, please refer to X Project website and subscribe to all social Media Handles.

uni Brands Corporation Celebrates Courage Towards the Future at TEDWomen 2023

Retrieved on: 
Wednesday, October 18, 2023
Courage, Name, Woman, TED (conference), Uni, TED, Partnership, Creativity, Imagination, Nightclub

ATLANTA, Oct. 18, 2023 /PRNewswire/ -- From starting lines to dotted lines. uni Brands Corporation proudly partnered with TEDWomen 2023: "Two steps forward" in Atlanta, GA, from October 11th to 13th. The conference celebrated those taking bold strides into the future, working unapologetically to make big dreams become reality. The speaker casting was formed by people working on new models of equity and inclusion or blazing trails as pioneers, with names such as actress Glenn Close, writer Laurel Braitman, and many more.

Key Points: 
  • uni Brands Corporation proudly partnered with TEDWomen 2023: "Two steps forward" in Atlanta, GA, from October 11th to 13th.
  • The conference celebrated those taking bold strides into the future, working unapologetically to make big dreams become reality.
  • Attendees were encouraged to actively participate in making their mark on the mural by coloring it with vibrant POSCA markers from uni.
  • "Through symbolic paths that intertwine, these visuals reflect the strength and determination of women embracing uncertainty with courage," says Pennerman.

The World's First AI-Created Digital Children's Spokesperson 'Uni' is Ready to Amplify the Voices of Children Around the World

Retrieved on: 
Tuesday, October 3, 2023
Uni, STEAM, Education, Face, UN General Assembly Resolution 60/147, Office of the Secretary-General's Envoy on Youth, Human, Dream, UN, Ageing, AI, Health, Mental health, General assembly, Safety, Toy, Entertainment, Child

Uni is now ready to amplify the voices of children bringing their perspectives and solutions to global leaders and serving as an inspiration for creative approaches to tackle challenges.

Key Points: 
  • Uni is now ready to amplify the voices of children bringing their perspectives and solutions to global leaders and serving as an inspiration for creative approaches to tackle challenges.
  • BILLUND, DENMARK, Oct 3, 2023 - (ACN Newswire) - A manifesto and 40 ideas addressing the world's challenges have now been sent from the world's children to global leaders.
  • The children have returned home, but their solutions continue to be assembled in the world's first digital children's spokesperson called "Uni".
  • Uni is an AI created as an amalgamation of 80 faces and voices of the participants of Children's General Assembly and has helped amplify and deliver the messages of the world's children.

SECRET WALLS ACADEMY LAUNCHES "POSCA UNI-VERSITY", POWERED BY POSCA, TO INSPIRE TOMORROW'S ARTISTS AMID SHRINKING EDUCATION BUDGETS AND SPACE

Retrieved on: 
Wednesday, May 24, 2023
Partnership, Genetics, Curriculum, SW, Single person, Mentorship, FREE, Creativity, DIY, Pacific Time Zone, Student, Crash, Environment, Wotho Atoll, Uni, Interior design, Upendo Ni Pamoja

LOS ANGELES, May 24, 2023 /PRNewswire/ -- Introducing "POSCA uni-versity", the ultimate back-to-school partnership between Secret Walls and uni. As the new school year approaches, Secret Walls and uni are teaming up to help students unleash their creativity and express themselves like never before. With uni's vibrant and versatile line of POSCA paint markers and Secret Walls' unparalleled live paint battles, the partnership aims to educate, inspire, and support students to express themselves in bold new ways.

Key Points: 
  • LOS ANGELES, May 24, 2023 /PRNewswire/ -- Introducing "POSCA uni-versity", the ultimate back-to-school partnership between Secret Walls and uni.
  • As the new school year approaches, Secret Walls and uni are teaming up to help students unleash their creativity and express themselves like never before.
  • Introducing "POSCA uni-versity", the ultimate back-to-school partnership between Secret Walls and uni.
  • Sessions will take place IRL at Secret Walls HQ (2272 Venice Blvd, 90006) in Los Angeles on June 5th through 8th, from 12pm to 5:00pm Pacific Time.

EQS-News: Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 16, 2023
Marketing, Senior counsel, BGM, PPV, Hospital, Patient, R, Early Detection Research Network, Pancreas, Research, Gene expression, USD, EDRN, Growth, FDA, PCR, Pancreatic cancer, Cancer, Biomarker, IP, Messenger, NPV, Colorectal cancer, Mortality, Hand, Family, Labour, MAP, Uni, Partnership, CRC, Bank statement, Clinical trial, ASX, Physician, Form 6-K, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AA, Food, Pharmaceutical industry, Vaccine, Medical imaging

BERKELEY, US – MAINZ, Germany – May 16, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today first quarter results which ended March 31, 2023 and provided a corporate update.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – May 16, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today first quarter results which ended March 31, 2023 and provided a corporate update.
  • Throughout the first quarter, Mainz Biomed continued to prepare for commencing patient enrollment in the ReconAAsense study (ClinicalTrials.gov Identifier: NCT05636085) in H2 2023.
  • In addition and in synchronicity with this transaction, Mainz Biomed exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C.
  • The Company has filed a current report on Form 6-K on May 16, 2023, with the U.S. Securities and Exchange Commission, which includes both consolidated financial statements and management’s discussion and analysis of its financial results for the first quarter of 2023.

Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 16, 2023
Marketing, Senior counsel, BGM, PPV, Hospital, Patient, R, Early Detection Research Network, Pancreas, Research, Gene expression, USD, EDRN, Growth, FDA, PCR, Pancreatic cancer, Cancer, Biomarker, IP, Messenger, NPV, Colorectal cancer, Mortality, Hand, Family, Labour, MAP, Uni, Partnership, CRC, Bank statement, Clinical trial, ASX, Physician, Form 6-K, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AA, Food, Vaccine, Medical imaging, Pharmaceutical industry

BERKELEY, Calif. and MAINZ, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today first quarter results which ended March 31, 2023 and provided a corporate update.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today first quarter results which ended March 31, 2023 and provided a corporate update.
  • Throughout the first quarter, Mainz Biomed continued to prepare for commencing patient enrollment in the ReconAAsense study (ClinicalTrials.gov Identifier: NCT05636085) in H2 2023.
  • In addition and in synchronicity with this transaction, Mainz Biomed exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C.
  • The Company has filed a current report on Form 6-K on May 16, 2023, with the U.S. Securities and Exchange Commission, which includes both consolidated financial statements and management’s discussion and analysis of its financial results for the first quarter of 2023.

EQS-News: Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

Retrieved on: 
Wednesday, February 22, 2023
Biomarker, Physician, Uni, Messenger, PPV, Colorectal cancer, Patient, University, Gene expression, FDA, Conditional sentence, IP, CRC, AA, US Foods, NPV, Cancer, Sherbrooke, Vaccine

BERKELEY, US – MAINZ, Germany – February 21, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property (“IP”) for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer (“CRC”) being commercialized across Europe.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – February 21, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property (“IP”) for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer (“CRC”) being commercialized across Europe.
  • Simultaneously, the Company also exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C.
  • “This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed.
  • This particular portfolio of mRNA biomarkers selected by Mainz Biomed was based on work in the field by the University of Sherbrooke, where researchers tested multiple novel transcriptional biomarkers using colorectal cancer and precancerous lesion samples.

Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

Retrieved on: 
Tuesday, February 21, 2023
Biomarker, Physician, Uni, Messenger, PPV, Colorectal cancer, Patient, University, Gene expression, FDA, Conditional sentence, IP, CRC, AA, US Foods, NPV, Cancer, Sherbrooke, Vaccine

BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property (“IP”) for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer (“CRC”) being commercialized across Europe. Simultaneously, the Company also exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C. (“SOCPRA”), to outright purchase IP, including a pending patent, associated with a portfolio of novel gene expression (mRNA) biomarkers that have demonstrated ability to detect CRC lesions, including advanced adenomas (“AA”), a type of pre-cancerous polyp often attributed to this deadly disease.

Key Points: 
  • Simultaneously, the Company also exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C.
  • “This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed.
  • Mainz Biomed is commercializing ColoAlert across Europe and in select international markets through a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • This particular portfolio of mRNA biomarkers selected by Mainz Biomed was based on work in the field by the University of Sherbrooke, where researchers tested multiple novel transcriptional biomarkers using colorectal cancer and precancerous lesion samples.